- Advertisement -
QUEENSBURY, N.Y.–(BUSINESS WIRE)–Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025…
Click here to view the original article.
